Real-World Patient Characteristics, Treatment Patterns, and Blood Counts of Patients With Essential Thrombocythemia Treated With Ropeginterferon Alfa-2b in the US Community Oncology Setting (SOHO 2026) - Sep 1, 2026 - Abstract #MPN-1090; Location: LEVEL 3, HALL B3; "In patients with ≥1 prior cytoreductive therapy (n = 49), the most common 1L was hydroxyurea (92%), and median time from ET diagnosis to ropeginterferon initiation was 13 months. In patients with ≥2 prior cytoreductive therapies (n = 21), next cytoreductive therapies after 1L included anagrelide (43%), peginterferon (24%), and ruxolitinib (19%)... This analysis provides preliminary insights into real-world use and outcomes of ropeginterferon in patients with ET. Ropeginterferon was largely initiated after 1L but also as 1L for younger patients. Platelets and response rates trended towards optimal levels regardless of cytoreductive therapy history."
Clinical • Real-world • Real-world evidence • Essential Thrombocythemia • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera
|
|
Luke Fletcher MD 1; Priya Rudolph MD 2; Andrew Osterland PharmD,MS 3; Malcom Charles MS 3; Matthew Whitesell BS 3; Shinya Imada MD PhD 4; Shaoyu Chang MD,MPH 4; Albert Qin MD PhD 4; Ira Zackon MD 3; Solly Chedid MD 5
|